{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:15:47Z","timestamp":1790104547369,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":2607,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","award":["KKS 689"],"award-info":[{"award-number":["KKS 689"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","award":["KKS 738"],"award-info":[{"award-number":["KKS 738"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1093\/annonc\/mds055","type":"journal-article","created":{"date-parts":[[2012,3,31]],"date-time":"2012-03-31T03:49:22Z","timestamp":1333165762000},"page":"2566-2572","source":"Crossref","is-referenced-by-count":20,"title":["Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM"],"prefix":"10.1016","volume":"23","author":[{"given":"P.","family":"Hadji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.G.","family":"Kieback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Tams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hasenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ziller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1093\/annonc\/mds055_bb0010","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/annonc\/mdp322","article-title":"Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009","volume":"20","author":"Goldhirsch","year":"2009","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mds055_bb0015","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0960-9776(09)70002-5","article-title":"Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer","volume":"18","author":"Chlebowski","year":"2009","journal-title":"Breast"},{"issue":"9561","key":"10.1093\/annonc\/mds055_bb0020","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","article-title":"Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial","volume":"369","author":"Coombes","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"10.1093\/annonc\/mds055_bb0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"Forbes","year":"2008","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1093\/annonc\/mds055_bb0030","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1056\/NEJMoa0810818","article-title":"Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer","volume":"361","author":"Mouridsen","year":"2009","journal-title":"N Engl J Med"},{"issue":"Suppl 8","key":"10.1093\/annonc\/mds055_bb0035","doi-asserted-by":"crossref","first-page":"viii26","DOI":"10.1093\/annonc\/mdm263","article-title":"Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer","volume":"18","author":"Perez","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds055_bb0040","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1677\/ERC-07-0193","article-title":"Menopausal symptoms and adjuvant therapy-associated adverse events","volume":"15","author":"Hadji","year":"2008","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"10.1093\/annonc\/mds055_bb0045","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1200\/JCO.2005.11.005","article-title":"Selective estrogen-receptor modulators for primary prevention of breast cancer","volume":"23","author":"Fabian","year":"2005","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mds055_bb0050","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1634\/theoncologist.2008-0055","article-title":"Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?","volume":"13","author":"Miller","year":"2008","journal-title":"Oncologist"},{"issue":"3","key":"10.1093\/annonc\/mds055_bb0055","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ctrv.2007.10.004","article-title":"Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations","volume":"34","author":"Coleman","year":"2008","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"10.1093\/annonc\/mds055_bb0060","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/annonc\/mdn762","article-title":"Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised sub-study","volume":"20","author":"Hadji","year":"2009","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1093\/annonc\/mds055_bb0065","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","article-title":"Practical guidance for the management of aromatase inhibitor-associated bone loss","volume":"19","author":"Hadji","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds055_bb0070","doi-asserted-by":"crossref","unstructured":"Amir E, Ocana A, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients Oral presentation at San Antonio Breast Cancer Symposium (SABCS). San Antonio, TX 2010.","DOI":"10.1158\/0008-5472.SABCS10-S2-7"},{"issue":"11","key":"10.1093\/annonc\/mds055_bb0075","first-page":"23","article-title":"Can rash associated with HER1\/EGFR inhibition be used as a marker of treatment outcome?","volume":"17","author":"Perez-Soler","year":"2003","journal-title":"Oncology (Williston Park)"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mds055_bb0080","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.3816\/CLC.2006.s.008","article-title":"Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer","volume":"8","author":"Perez-Soler","year":"2006","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"10.1093\/annonc\/mds055_bb0085","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10549-007-9612-x","article-title":"Tamoxifen, hot flashes and recurrence in breast cancer","volume":"108","author":"Mortimer","year":"2008","journal-title":"Breast Cancer Res Treat"},{"issue":"9762","key":"10.1093\/annonc\/mds055_bb0090","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(10)62312-4","article-title":"Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial","volume":"377","author":"van de Velde","year":"2011","journal-title":"Lancet"},{"issue":"10","key":"10.1093\/annonc\/mds055_bb0095","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1001\/archotol.132.10.1041","article-title":"Association between development of hypothyroidism and improved survival in patients with head and neck cancer","volume":"132","author":"Nelson","year":"2006","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"9","key":"10.1093\/annonc\/mds055_bb0100","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1093\/annonc\/mds055_bb0105","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S1470-2045(08)70259-6","article-title":"Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial","volume":"9","author":"Cuzick","year":"2008","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1093\/annonc\/mds055_bb0110","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1200\/JCO.2006.06.8072","article-title":"Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial","volume":"24","author":"Bonanni","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mds055_bb0115","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10549-006-9428-0","article-title":"The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen","volume":"101","author":"Goetz","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"36","key":"10.1093\/annonc\/mds055_bb0120","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1200\/JCO.2005.03.3266","article-title":"Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes","volume":"23","author":"Goetz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds055_bb0125","doi-asserted-by":"crossref","unstructured":"Stearns V, Chapman J-A, Ma C, et al. Treatment-emergent symptoms and the risk of breast cancer recurrence in the NCIC CTG MA.27 adjuvant aromatase inhibitor trial Oral presentation at San Antonio Breast Cancer Symposium (SABCS). San Antonio, TX 2009","DOI":"10.1158\/0008-5472.SABCS-09-14"},{"issue":"4","key":"10.1093\/annonc\/mds055_bb0130","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2007.11.5451","article-title":"Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer","volume":"26","author":"Partridge","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1\u20132","key":"10.1093\/annonc\/mds055_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000100444","article-title":"Adherence to endocrine therapy for breast cancer","volume":"71","author":"Chlebowski","year":"2006","journal-title":"Oncology"},{"issue":"3","key":"10.1093\/annonc\/mds055_bb0140","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/annonc\/mdn646","article-title":"Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer","volume":"20","author":"Ziller","year":"2009","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1093\/annonc\/mds055_bb0145","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.critrevonc.2009.02.001","article-title":"Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy","volume":"73","author":"Hadji","year":"2010","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419379475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419379475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/10\/2566\/13786238\/mds055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:25:15Z","timestamp":1624519515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419379475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0923753419379475"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds055","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}